key: cord-0826939-0qrcdhbx authors: Chou, Feng-Pai; Liu, Chia-Chun; Huong Giang, Huynh Nguyet; Huang, Sheng-Cih; Hsu, Hsiu-Fu; Wu, Tung-Kung title: Evaluation of RevX Solution Extract as a Potential Inhibitor of the Main Protease of SARS-CoV-2—In vitro Study and Molecular Docking date: 2022-02-28 journal: Heliyon DOI: 10.1016/j.heliyon.2022.e09034 sha: 3169dd73a75b0fd4a0cf8ae572da0d26793b7cc7 doc_id: 826939 cord_uid: 0qrcdhbx The main protease (M(pro)) of SARS-CoV-2 is a protease necessary for viral polyprotein processing and maturation. M(pro) cleaves the polypeptide sequence after the glutamine residues. There is no known cellular protease with this substrate specificity in humans; therefore, it is considered an attractive drug target. Previously, fermented sorghum extract RevX (trademark of Revolutrx INC.) solution significantly alleviated physical decline and complications in a patient with lung adenocarcinoma, suggesting the role of bioactive components in RevX solution. To further explore whether the bioactive components in RevX solution exhibit other biological activities, such as antiviral effects, we investigated its inhibitory effect on the M(pro) of SARS-CoV-2 virus. We report herein that the solid extract of the RevX solution exhibits an efficacious M(pro) inhibitory activity, with IC(50) of 2.07 ± 0.38 μg/mL. Molecular docking of sterol-like components in the RevX extracts identified by MS shows that the three sterol-like molecules can bind to the active region of the GC376-M(pro) complex, supporting the structure-function relationship. Combined with its ability to significantly alleviate the body’s immunity decline and to inhibit the activity of SARS-CoV-2 M(pro), RevX solution may provide a possible alternative supportive treatment for patients with COVID-19. The 2019 global pandemic coronavirus disease , caused by severe 53 acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2), has caused high 54 morbidity and mortality, and severe social, economic, and political chaos. As of 16 55 November 2021, the number of confirmed cases has exceeded 253.26 million, and the 56 death toll has surpassed 5.11 million 57 protease has a unique substrate preference for glutamine at the P1 position of the 104 polyprotein (Leu-Gln↓(Ser, Ala, Gly)) and, specifically, cleaves the peptide sequence 105 after the glutamine residues (Rut et al., 2021) . There is no known cellular protease with 106 such substrate specificity in humans (Hilgenfeld, 2014; Zhang et al., 2020 The RevX solution extracts were obtained according to the following procedures. 160 First, 600 mL of RevX solution was gently removed the solvent by rotary evaporation 161 to obtain the solid (S) fraction. By dissolving it in 30 mL CCl4 and 30 mL ddH2O, the 162 solid extract (S) was used to prepare the water (W) or organic (L) fractions using the 163 following procedure: Collect the first organic layer (L1), add 30 mL of CCl4 to the water 164 layer, repeat the extraction, and collect the organic layer (L2). Then add 30 mL of water 165 for extraction and repeat the above process again to collect the organic layer (L3). After 166 collecting the organic layer, the remaining water layer was marked as W1, and add 30 167 mL of water to L1 + L2 + L3 for extraction, and collect the water layer as W2. Then, 168 add 30 mL of water for extraction and repeat the above process to obtain W3. Removing The instrument was initially set at 50 ˚C, then ramped up to 300˚C at a rate of 10 ˚C/min, 177 then held at 300 ˚C for 10 minutes. The inlet temperature was set at 300 ˚C. The column 178 uses helium as the carrier gas, which is flowed at a constant rate of 1 mL/min. Electron and electrostatic or hydrogen bonding interactions between amino acid residues and 295 ligands (Fig. 3) . The glutamine surrogate of GC376 (P1 position) forms H-bonds with 296 His163 and Glu166 and hydrophobic interactions with His172. The Leu of GC376 (P2 297 position) inserted into the S2 hydrophobic pocket consisting of Arg40, His41, Cys44, 298 Met49, Tyr54, Met165, Arg188 and Gln189. The benzyl ring of GC376 (P3 position) 299 fits into the S1 binding site and forms a H-bond with the side chain carboxyl group of 300 Glu166. The hydrophobic and hydrogen bonding interactions of these residues form a 301 support for drug binding (Fu et al., 2020) . The backbones of Gly143, Ser144, and 302 Cys145 form the oxyanion hole. Previously, the flexibility of M pro was as pH-dependent 303 as SARS-CoV M pro (Tan et al., 2005) . Proteins were found to be most stable at neutral 304 pH. Basic protein structures become the most unstable with changes in pH, and acidic 305 pH also tended to alter the structural properties of M pro . When docking experiments 306 were performed at pH 4, 5, 6, 7, and 8, it was assumed that all acidic amino acids (Asp 307 and Glu) were deprotonated, while basic amino acids (Arg, Lys, and Cys) were 308 protonated in this pH range. In addition, the protonation states of catalytic His41 and 309 Cys145 were not changed. The protonation state of all other 12 His residues present in 310 the protein changes by changing the partial charge on the atoms of the titratable residue. Cys145 was only observed at pH 7, but a distorted or wrong orientation was present at 315 all pH values except pH 7. Therefore, in this study, the amino acid residues used in the 316 docking experiments included His41, Cys44, Leu141, Gly143, Asn142, Gly143, 317 Ser144, Cys145, His163, His164, Met165, Glu166, Arg188, and Gln189 as active sites 318 (Fig. 3) . 319 J o u r n a l P r e -p r o o f Pro168, Gln189, Ala191, and Gln192. The hydroxyl group at the C3 site forms 336 hydrogen bonds with the backbone amide groups of Gly143, Ser144, and Cys145 and 337 the carbonyl oxygen of Leu141 and Ser144 (Fig. 4) . 338 and His163 (Fig. 6) . The O1 hydroxyl atom at the C3 site of J11 forms a hydrogen bond 361 with Cys44. The O2 hydroxyl group at the C24 position forms a hydrogen bond with 362 N2 of His163, and the O3 hydroxyl group at the C25 site forms hydrogen bonds with 363 the amide groups of Gly143, Ser144, and Cys145 and the carbonyl oxygen of Leu141 364 and His163. 365 Sorghum bicolor L.): Nutrients, bioactive compounds, and potential 417 impact on human health COVID-19: A collision of complement, 419 coagulation and inflammatory pathways Discovering severe 421 acute respiratory syndrome coronavirus 3CL protease inhibitors: virtual 422 screening, surface Plasmon resonance, and fluorescence resonance energy 423 transfer assays Phytochemicals containing biologically active polyphenols as an effective agent 426 against Covid-19-inducing coronavirus COVID-430 19: staging of a new disease comment PyMOL: An open-source molecular graphics tool Glycyrrhetinic acid and 434 its derivatives as potential alternative medicine to relieve symptoms in 435 nonhospitalized COVID-19 patients SARS-CoV -a target for vaccine and therapeutic development Polyprotein cleavage mechanism of SARS CoV Mpro and chemical 441 modification of the octapeptide Coronaviruses: an overview of their replication and 446 pathogenesis Both Boceprevir and GC376 449 efficaciously inhibit SARS-CoV-2 by targeting its main protease Isolation and characterization of a bat SARS-452 like coronavirus that uses the ACE2 receptor Comparative host-455 coronavirus protein interaction networks reveal pan-viral disease mechanisms Evidence that vitamin D supplementation could reduce risk 459 of influenza and COVID-19 infections and deaths The molecular virology of coronaviruses From SARS to MERS: crystallographic studies on coronaviral 463 proteases enable antiviral drug design iGEMDOCK: a graphical 465 environment of enhancing GEMDOCK using pharmacological interactions and 466 post-screening analysis Chymotryptic 468 hydrolysates of -kafirin, the storage protein of sorghum exhibited angiotensin converting enzyme inhibitory activity Room temperature X-ray crystallography reveals 473 oxidation and reactivity of cysteine residues in SARS-CoV-2 3CL Mpro: 474 Insights for enzyme mechanism and drug design Therapeutic options for the 2019 novel coronavirus (2019-476 nCoV) Ginkgolic acid inhibits HIV protease 478 activity and HIV infection in vitro Effect of RevX solution adjunct to standard therapy in a patient with 480 metastatic lung adenocarcinoma: A case report Experimental and 482 computational approaches to estimate solubility and permeability in drug 483 discovery and development settings Genomic characterisation 485 and epidemiology of 2019 novel coronavirus: implications for virus origins and 486 receptor binding. The lancet Molecular docking: a powerful 488 approach for structure-based drug discovery Evaluation of sorghum 490 (Sorghum bicolor) as replacement for maize in the diet of growing rabbits 491 Sorghum bicolor with targets related to diabetes mellitus Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel 497 broad-spectrum oral antiviral agent Roles of 500 flavonoids against coronavirus infection CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging Torreya nucifera displaying SARS-CoV 3CLpro inhibition Probable molecular mechanism of remdesivir for the treatment of COVID-19: 511 need to Know more Herbal medicine for 514 cardiovascular diseases: efficacy, mechanisms, and safety Quantitative 517 analysis of anticancer 3-deoxyanthocyanidins in infected sorghum seedlings pH-dependent Conformational Flexibility of the SARS-520 CoV Main Proteinase (Mpro) Dimer: Molecular Dynamics Simulations and 521 Multiple X-ray Structure Analyses The SARS-CoV-2 main protease as drug target Feline 525 coronavirus drug inhibits the main protease of SARS-CoV-2 and blocks virus 526 replication Protective 528 effects of Ginkgo biloba Dropping Pills against liver ischemia/reperfusion 529 injury in mice Terpenoids and Lignoids possess potent antiviral activities against severe acute 532 respiratory syndrome coronavirus Structural biology of SARS-CoV-2 and implications for 534 therapeutic development Sorghum 3-deoxyanthocyanins possess 536 strong phase II enzyme inducer activity and cancer cell growth inhibition 537 properties Crystal structure of SARS-CoV-2 main protease 540 provides a basis for design of improved α-ketoamide inhibitors Crystal structure of SARS-CoV-2 main protease 543 provides a basis for design of improved α-ketoamide inhibitors The authors declare that they have no conflicts of interest 413